Targeting the COX-2 Pathway to Improve Therapeutic Response in the Obese Breast Cancer Patient Population

Abstract

Multiple studies have demonstrated that obesity is associated with a worse outcome for all breast cancer subtypes and that obese breast cancer patients do not respond as well as normal weight patients to aromatase inhibitor treatment and chemotherapy. While a number of mechanisms have been proposed to explain this link, recent studies have provided evidence that elevated local cyclooxygenase-2 (COX-2) expression and the resulting increase in prostaglandin E2 (PGE2) production may play an important role. COX-2 upregulation in breast tumors is associated with a poor prognosis, a connection generally attributed to PGE2’s direct effects on apoptosis and invasion as well as its stimulation of pre-adipocyte aromatase expression and subsequent estrogen production. Research in this area has provided a strong foundation for the hypothesis that COX-2 signaling is involved in the obesity-breast cancer link, and further study regarding the role of COX-2 in this link is warranted.

Introduction

Over the past 30 years, obesity has become a significant global health problem. In the United States, the adult obesity rate has risen over that time period to a current rate of 35.7% [1], and similar trends are evident worldwide [2]. Given the association between excess adiposity and an increased incidence of and mortality from numerous chronic diseases, this elevation in obesity rates presents a serious threat to public health. In addition to promoting the development of cardiovascular disease, diabetes mellitus, and hypertension, obesity has been shown to enhance the risk and progression of several types of cancer, including breast cancer.

In postmenopausal women, obesity increases breast cancer risk by approximately 40% [3–5]. While most research has indicated that obesity actually protects premenopausal women from breast cancer, a recent study suggests that the interaction may be more complex, differing with presence of other risk factors [6, 7]. A large body of evidence has established that obesity is also associated with a worse breast cancer prognosis for both pre- and postmenopausal women. One prospective study found that the breast cancer mortality rate escalates with each successive increase in BMI category [8]. Another study showed a significantly greater risk for disease recurrence within 10 years of diagnosis in breast cancer patients who were obese at the time of treatment in comparison to non-obese patients [9]. These effects could be due to later diagnosis in the obese population, resulting in more advanced disease at the time of diagnosis. However, while Majed et al. [10] reported that the obese patients from a large cohort followed for 20 years presented with more advanced tumors, suggesting that diagnosis had been delayed, the authors ultimately found that multivariate statistical analysis demonstrated an independent effect of obesity on breast cancer prognosis. Survival analysis revealed increased metastatic recurrence as well as decreased disease-free interval and overall survival in the obese patient population. Additional studies have produced similar findings supporting the link between obesity and a worse prognosis [11*, 12].

A number of mechanisms have been proposed to explain this obesity-breast cancer connection, including abnormalities in the circulating levels of estrogens, insulin, insulin-like growth factor, leptin, adiponectin, vascular regulators, and inflammatory cytokines [13]. However, exploration of these signaling molecules has thus far not produced any improvement in the treatment regimen for obese breast cancer patients. Recent studies suggesting the cyclooxygenase 2 (COX-2) enzyme may be an important mediator of the obesity-breast cancer link have sparked interest in this pathway as a potential druggable target for the obese patient population. Here we review the evidence regarding the hypothesis that COX-2 plays a significant role in obesity-associated breast cancer progression and examine whether its inhibition may improve obese patient outcome.

COX-2 and breast cancer progression

Most healthy tissues do not express detectable levels of COX-2, the enzyme responsible for catalyzing the conversion of arachidonic acid into a number of different prostanoids. However, it can be highly induced in several tissue types as part of the inflammatory response and is thus a key pharmaceutical target for the reduction of pain and inflammation [14]. Upregulation of this protein has also been found in many human cancers, including 40% of breast tumors [15]. Of the prostanoids, the pro-inflammatory prostaglandin E2 (PGE2) is found in the highest concentrations within breast tumor tissue and is known to promote breast cancer progression [16]. Consequently, it is not surprising that high COX-2 expression levels have been found to be correlated with a poor breast cancer outcome. Ristimäki et al. [17] demonstrated that elevated COX-2 expression in invasive breast tumors was associated with decreased distant tumor-free survival as well as various negative prognostic indicators, including a larger tumor size, higher histological grade and proliferation rate, negative hormone receptor status, and the presence of axillary metastases. Another research group reporting a link between high COX-2 expression in Stage I–III breast tumors and a lower survival rate found that this was independent of tumor size and grade as well as estrogen receptor alpha (ERα), HER2, and nodal status [18]. COX-2 positivity was similarly correlated with a 35% increase in the risk of breast cancer death in a study of stage I–IV breast tumors, but this difference in risk was no longer statistically significant after adjustment for tumor stage at diagnosis [19]. Park et al. [20] also found an association between COX-2 status and a worse breast cancer survival, but only in proliferative breast tumors. Despite these variations in results, which may be due to differences in study population, methodology, and patient subset risk, the preponderance of the evidence supports the premise that elevated COX-2 expression is linked to a worse breast cancer outcome.

Animal model and cell culture experiments provide further data suggesting that COX-2 upregulation can promote breast cancer progression. They also demonstrate that this effect is mediated by inhibition of apoptosis as well as stimulation of cell migration, invasion, and possibly proliferation. For example, overexpression of COX-2 in the mammary gland has been shown to be sufficient to induce the development of mammary tumors in mice, and these tumors exhibit an anti-apoptotic protein expression profile [21]. Another study found that treatment with the COX-2 inhibitor celecoxib arrested the growth of MDA-MB-231 breast cancer cells in vitro via the induction of apoptosis. In a xenograft mouse model using the same cells, inhibition of tumor growth with celecoxib treatment was accompanied by less vascularization and greater tumor necrosis [22]. COX-2 has also been strongly linked to greater breast cancer cell metastatic capability. In one study, COX-2 overexpression enhanced the ability of MDA-435S breast cancer cells to metastasize to the bones of nude mice, while inhibition of COX-2 reduced bone metastasis burden [23]. The role of COX-2 in promoting breast cancer metastasis is further supported by a study showing that a fibroblast-induced increase in invasive capacity in a xenograft model of human DCIS was reversed with COX-2 inhibitor treatment [24]. Cell culture studies have also demonstrated that COX-2 overexpression in MDA-MB-231 cells leads to an increase in cell migration and invasion [25]. In contrast, while PGE2 induces proliferation in both colon and lung cancer cells [26, 27], its effect on breast cancer cell proliferation is unclear. Several studies have concluded that PGE2 does stimulate breast cancer cell proliferation based on the ability of COX-2 inhibitors to suppress proliferation in these cells [28, 29]. However, Robertson et al. [30] reported no increase in MDA-MB-231 cell proliferation following PGE2 treatment. Indirectly, PGE2 may promote the proliferation of ERα positive breast cancer cells by stimulating pre-adipocyte aromatase expression and the subsequent production of estradiol within breast tissue adjacent to the tumor [31]. Previous pre-clinical studies have demonstrated that PGE2, derived from macrophages and other sources, is a potent stimulant of pre-adipocyte aromatase expression [32, 33]. Together, these studies provide a large body of evidence supporting COX-2’s ability to promote breast cancer progression via multiple mechanisms (Fig. 1).

Fig. 1.

Obesity, COX-2 expression, and breast cancer progression. Obesity stimulates local COX-2 expression in the breast through multiple mechanisms, leading to increased PGE2 production that directly and indirectly promotes breast cancer progression. With the increase in adipocyte necrosis that typically accompanies obesity, there is a rise in macrophage infiltration into the breast adipose tissue. COX-2 expression in these macrophages is enhanced by an obesity-associated elevation in circulating saturated fatty acid levels, which are the result of a higher rate of lipolysis. In addition, circulating interleukin 6 levels are typically elevated with obesity, and this may induce greater breast cancer cell COX-2 expression. PGE2 production by both cell types may also be increased with obesity by higher serum arachidonic acid levels. This PGE2 can directly stimulate migration and invasion and inhibit apoptosis in breast cancer cells. It can also indirectly affect breast cancer cell proliferation, migration, and apoptosis via its induction of pre-adipocyte aromatase expression and estradiol production. COX-2: cyclooxygenase-2; E: estradiol; EP: prostaglandin receptor; ERα: estrogen receptor alpha; PGE2: prostaglandin E2

Obesity and COX-2 expression

While obesity has been shown to negatively impact breast cancer outcome for all tumor subtypes in both pre- and postmenopausal patients, the most prominent effects are seen in ERα positive postmenopausal patients, a finding confirmed by a recent retrospective analysis of the German BRENDA-cohort [34]. Obesity has been hypothesized to negatively impact outcomes in this patient population by promoting adipose tissue expression of aromatase, the rate-limiting enzyme in the production of estradiol from testosterone. Due to an abundance of this aromatase-expressing tissue, obese postmenopausal women typically have higher levels of circulating estradiol [35–37], and researchers have posited that this may contribute to the observed increase in breast cancer risk. However, aromatase expression in breast tumors and their associated adipose tissue is typically five-fold higher than the levels found in disease-free breast tissue, and this is accompanied by a 10-fold elevation in estradiol concentration in comparison to serum levels [38]. This suggests that increased circulating estradiol is likely not a contributor to obesity-induced breast cancer progression, but enhanced local aromatase expression and estradiol production may be playing a role

Recent studies by Dannenberg and colleagues confirmed the presence of elevated aromatase expression in the breast tissue of overweight and obese women with and without breast cancer. They also demonstrated high congruence between obesity and local breast tissue aromatase levels and inflammation, the latter measured by the number of crown-like structures (CLS-B). CLS-B are inflammatory foci within the breast adipose tissue that are composed of a necrotic adipocyte surrounded by macrophages, which can express high levels of COX-2. In fact, breast tissue inflammation and aromatase expression were also positively correlated with levels COX-2 and PGE2 [39**, 40].

In addition to promoting the incidence of these CLS-B, obesity is associated with other factors that may further increase COX-2 levels in adipose-infiltrating macrophages. Saturated fatty acids can stimulate COX-2 expression and PGE2 secretion by cultured macrophages [32, 41], and the increased lipolysis that occurs with obesity results in a higher concentration of circulating free fatty acids [42–44]. Consequently, the obesity-associated elevation in breast tissue aromatase levels may also be due to free fatty acid-induced macrophage COX-2 expression. Obesity is also typically accompanied by increased circulating levels of several cytokines that may further enhance local COX-2 expression. For example, serum concentrations of IL-6 and TNFα are generally increased with obesity [45], and these cytokines have been shown to promote PGE2 production in multiple cell types via their effects on COX-2 expression [46, 47].

Our recent findings support the possibility that higher concentrations of circulating saturated fatty acids and/or cytokines may promote greater macrophage COX-2 expression in the breast tissue of obese women. We demonstrated that cultured macrophages exposed to sera from obese postmenopausal women expressed higher levels of COX-2 mRNA and produced more PGE2 in comparison to cells cultured in sera from normal weight women, and the obese patient sera contained higher concentrations of saturated fatty acids, interleukin-6 and tumor necrosis factor alpha [48*, 49]. Through a series of direct and indirect co-culture experiments, we found that this obese patient sera-induced elevation in macrophage COX-2 expression and PGE2 production could stimulate increased adipocyte aromatase expression, resulting in greater breast cancer cell ERα activity, proliferation, and migration [48*]. These results suggest that increased local COX-2 and aromatase expression could be a significant contributor to the worse outcome observed in obese postmenopausal patients with ERα positive breast cancer.

To our knowledge, no one has published data regarding the impact of obesity on breast cancer epithelial cell COX-2 expression in humans. However, in vitro studies from our laboratory indicate that exposure to sera from obese women promotes greater breast cancer cell COX-2 expression and PGE2 production in comparison to normal weight patient sera [50]. In addition, Stephen Hursting’s laboratory has found that diet-induced obesity promotes mammary tumor growth and higher tumor COX-2 expression and PGE2 levels in a xenograft model utilizing two mammary tumor cell lines isolated from the MMTV-Wnt-1 transgenic mouse (personal communication). Together, this data strongly suggests that obesity may induce higher breast tumor COX-2 expression in vivo. Given the association between elevated breast tumor COX-2 levels and poor prognosis, further examination of the impact of obesity on breast tumor COX-2 expression is warranted.

NSAID use and breast cancer progression

Non-steroidal anti-inflammatory drugs (NSAIDs) are taken daily by many individuals for a variety of reasons, including cardiovascular disease prevention and pain relief. This group of drugs, which include aspirin, ibuprofen and naproxene, specifically target COX-2 and inhibit multiple inflammatory pathways. The link between an elevated COX-2 expression and poor breast cancer prognosis has thus spurred great interest in determining whether NSAID use is associated with a better patient outcome. With the increasing evidence that both macrophage and breast cancer cell COX-2 expression may be significant mediators of obesity-associated breast cancer progression, the impact of NSAID use on the obese breast cancer patient population should be specifically assessed. We recently demonstrated that daily NSAID use in patients with invasive ERα positive breast cancer receiving adjuvant endocrine therapy was correlated with a 52% lower recurrence rate. NSAID users in this patient population also remained disease-free for more than two years longer than non-users [48*]. Some much larger prospective studies examining NSAID use following breast cancer diagnosis have also shown positive associations with various measures of disease outcome, but to our knowledge only one has reported a variance of similar magnitude [51]. We hypothesized that our results may be attributable to the overwhelming incidence of overweight and obesity in our patient population, which had an average body mass index (BMI) of 31 kg/m². This hypothesis is supported by our cell culture experiments demonstrating that sera from obese postmenopausal women stimulates higher macrophage and breast cancer cell COX-2 expression and PGE2 production in comparison to cells cultured in sera from normal weight women, as discussed above.

Cumulatively, other studies that have examined the impact of NSAID use on breast cancer patient outcome appear to indicate that it may be an effective addition to adjuvant breast cancer treatment, regardless of BMI, ERα, or menopausal status (Table 1). However, the variability in design and patient population among these studies makes any comparison to our results difficult. In an examination of stage I–III breast cancer patients from the Nurses’ Health Study, aspirin use 6–7 days/week was associated with a significant reduction in the risk of distant recurrence (RR, 0.57; 95% CI, 0.39–0.82), and stratification of the subjects by BMI, menopausal status, and ERα status did not alter this result [51]. Blair et al. [52] reported that any amount of regular NSAID use was correlated with a lower risk of breast cancer death (HR, 0.64; 95% CI, 0.39–1.05) in postmenopausal patients. Adjustment for BMI category did not change this association, but its statistical significance was reduced by adjustment for ERα status. Another study specifically examining the post-diagnostic use of COX-2 inhibitors found that incidence of bone metastases was significantly reduced among users (OR, 0.11; 95% CI, 0.02–0.88) [53]. In contrast with these studies, ibuprofen (RR, 0.56; 95% CI, 0.32–0.98), but not aspirin (RR, 1.09; 95% CI, 0.74–1.61), use ≥3 days/week reduced the recurrence rate in a population of pre and postmenopausal breast cancer patients [54], and these results did not change after controlling for BMI, menopausal status, and ERα.

Table 1.

Prospective observational studies of NSAID use and breast cancer outcome

Subject Population	Type/frequency of NSAID	Outcome Measure(s) Used	Number of Subjects	Diagnosis Period	Follow-up Period
Iowa Women’s Health Study, Postmenopausal women with invasive breast cancer (Blair et al. 2007)	All NSAIDs; any frequency	Breast cancer and all-cause mortality	591	1986–1992	1992–2001
Life After Cancer Epidemiology (LACE) Study, Pre- and postmenopausal women with invasive breast cancer (Kwan et al. 2007)	All NSAIDs; ≥3 days/week	Breast cancer recurrence	2292	1997–2000	2000–2006
Nurse’s Health Study, Pre- and postmenopausal women with stage I–III breast cancer (Holmes et al. 2010)	Aspirin only; 1, 2–5, and 6–7 days/week	Breast cancer mortality and distant recurrence	4164	1976–2002	1980–2006

Despite the lack of change in these studies’ results with adjustment for or stratification by BMI category, the evidence from our research suggests that overweight and obese breast cancer patients may derive the greatest benefit from NSAID use. The patient population in our study was also largely postmenopausal and included only hormone responsive patients. Because obesity is associated with higher COX-2 and PGE2 levels and aromatase expression in female breast tissue [39, 40], it seems likely that the efficacy of NSAIDs in a postmenopausal, ERα positive patient population would increase with greater adiposity. In this population, the addition of daily NSAID use to aromatase inhibitor treatment may improve response to the endocrine therapy by reducing production of aromatase-promoting PGE2. In fact, NSAID use in postmenopausal women has been shown to be correlated with significantly lower serum estradiol levels after adjusting for age and BMI [55]. Perhaps the lack of variation in effect among BMI categories in previous studies of NSAID is due to their failure to stratify the data by BMI, ERα, and menopausal status simultaneously. This question could potentially be addressed by assessing the clinical benefit of a COX-2 inhibitor/aromatase inhibitor combination treatment in obese and normal weight postmenopausal, hormone-responsive breast cancer patients.

Clinical trials of COX-2 inhibitors

Several studies have established that obese postmenopausal women do not respond as well as their normal weight counterparts to aromatase inhibitor treatment. An analysis of data from the ATAC trial demonstrated that obese breast cancer patients receiving the aromatase inhibitor anastrozole had a significantly greater risk of recurrence. In addition, while recurrence-free survival with anastrozole treatment was higher in comparison to tamoxifen, this benefit was lost in the obese cohort [56*]. Another study found that although three extra years of anastrozole treatment decreased normal weight patients’ risk of disease recurrence and death by half, overweight and obese patients did not benefit from this treatment [57]. Furthermore, plasma estradiol and estrone sulfate levels in obese patients remain significantly elevated in comparison to non-obese patients following letrozole treatment [58], suggesting that this reduced response rate is related to suboptimal inhibition of obesity-associated aromatase activity. It is possible that an adjustment in the aromatase inhibitor dosage, which is prescribed at a fixed amount, may improve obese patient prognosis. However, that inference is confounded by two phase III clinical trials of anastrozole that found no overall benefit from a 10 mg dose (versus 1 mg), indicating that an increased dosage may not be effective in overcoming obesity-induced resistance to aromatase inhibitors [59, 60].

The research from our laboratory suggests that this obesity-associated aromatase inhibitor resistance may be at least partially due to an elevation in local aromatase expression resulting from increased macrophage and breast cancer cell COX-2 expression and PGE2 production. Consequently, we have hypothesized that the addition of a COX-2 inhibiting drug, like celecoxib, to aromatase inhibitor treatment could improve response in the obese ERα positive patient population. The clinical benefit of a celecoxib/aromatase inhibitor combination treatment has not been specifically examined in obese women, but trials of this drug regimen in the postmenopausal, hormone-responsive breast cancer patient population have generally showed a modest benefit with at least three months of combination treatment (Table 2). These studies have demonstrated trends towards more clinical complete response, longer duration of clinical benefit, and greater progression-free survival with the addition of celecoxib [61–63]. A small study assessing the impact of a 14-day pre-surgical regimen of celecoxib in postmenopausal breast cancer patients also found a non-significantly greater decrease in Ki67 staining with celecoxib treatment that the authors thought warranted further investigation [64]. None of these trials analyzed the treatment benefit by BMI category, so it is impossible to determine from this data whether overweight/obese women in this patient population are more likely to benefit from COX-2 inhibition. To our knowledge, no one has examined the efficacy of a COX-2 inhibitor/aromatase inhibitor combination in animal models of obesity and mammary carcinogenesis either.

Table 2.

Clinical trials of celecoxib +/− aromatase inhibitors or other chemotherapy for breast cancer

Trial/Subject Population	Drug Combination and Treatment Duration	Primary Outcome Measure(s)	Subject Number	Accrual Period	Follow-up Period
Celecoxib alone
Postmenopausal women (50–80 yrs of age) with Stage I–II breast cancer (Martin et al. 2010)	Randomized 2:1 to neoadjuvant celecoxib (400 mg bid) or no no treatment for 14 days	Change in Ki67 staining of core biopsy	23	NS	NA
Celecoxib + Aromatase Inhibitor
Postmenopausal women with hormone-sensitive breast cancer and progression after tamoxifen (Dirix et al. 2008)	Randomized to exemestane (25 mg/d) +/− celecoxib (400 mg bid)	Rate of clinical benefit	111	1/02–10/02	NS
Celecoxib Anti-Aromatase Neoadjuvant (CAAN) trial, postmenopausal women with invasive hormone-sensitive breast cancer (Chow et al. 2008)	Randomized to letrozole (2.5 mg/d) or exemestane (25 mg/d) +/− celecoxib (400 mg bid) for 3 mos neoadjuvant with treatment continued post-surgery for ≥2 yrs in responders	Clinical and pathological response	82	11/01–4/04	3 mos
Postmenopausal women with ER and/or PR positive metastatic breast cancer and lesions >1 cm diameter (Falandry et al. 2009)	Randomized to exemestane (25 mg/d) + celecoxib (400 mg bid, 6 mos) or placebo (5.6 mos)a	Progression-free survival	157	9/03–12/04	Median: 24 mos
Celecoxib + Other Chemotherapy
Pre- and postmenopausal women with metastatic breast cancer and recurrence with taxanes and/or anthracyclines (Fabi et al. 2008)	Single arm study: Capecitabine (1000 mg/m2 bid) on days 1–14 of 21 day cycle + celecoxib (200 mg bid) until disease progression or toxicity	Time to progression, safety	42	2/04–10/06	Median: 15 mos
Women aged 18–65 with stage II–III invasive breast cancer (Pierga et al. 2010)	Neoadjuvant 4 cycles epirubicin 75 mg/m2)-cyclophosphamide (750 mg/m2) then docetaxel (100 mg/m2) with randomization to concurrent celecoxib (400 mg bid) for HER2− patients with 3 wk cycles	Pathological tumor response	340	5/04–10/07	24 wks
Pre- and postmenopausal women with invasive breast cancer (Chow et al. 2013)	Single arm study: Neoadjuvant 4 cycles FEC (500, 100, 500 mg/m2) then 4 cycles docetaxel (100 mg/m2) + celecoxib (200 mg bid) with 3 wk cycles	Pathological complete response, objective response rate	64	2/06–1/10	Median: 50 mos

Abbreviations: bid: 2 times/day; d: day; FEC: 5-fluorouracil/epirubicin/cyclophosphamide; mos: months; NA: not applicable; NS: not specified; wk: week; yrs: years.

^aTime periods indicate median treatment duration as study was terminated prematurely due to reports of celecoxib’s cardiovascular toxicity.

Given that elevated COX-2 expression and PGE2 production have direct breast cancer promoting effects independent of their impact on aromatase expression, a few researchers have also conducted clinical trials to examine the benefit of COX-2 inhibitor treatment in combination with chemotherapy. Several studies have linked an elevated BMI with a poor response to chemotherapy, indicating a need for the development of more effective chemotherapeutic regimens for this patient population. For example, Del Fabbro et al. [65] found that overweight (BMI≥25 kg/m²) patients receiving neoadjuvant chemotherapy had a lower pathological complete response (pCR) and shorter progression-free survival in comparison to normal weight patients. Others have demonstrated a similar correlation between overweight status and a decreased chance of achieving pCR with neoadjuvant chemotherapy [66, 67]. These results are supported by reports that obesity is associated with a worse breast cancer outcome, including lower disease-free survival and overall survival, for all breast cancer subtypes treated with taxane agents [68, 69]. These findings, in conjunction with the data indicating an association between obesity and higher breast tissue COX-2 expression, suggest that obese patients could be particularly responsive to a COX-2 inhibitor/chemotherapy combination.

Collectively, clinical trials assessing the effects of this type of drug combination on breast cancer have found that various COX-2 inhibitor/chemotherapy regimens are effective and safe, but may not provide further benefit over chemotherapy alone (Table 2). One phase II study examining the addition of concurrent celecoxib to a neoadjuvant regimen of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) followed by docetaxel demonstrated that the COX-2 inhibitor was well-tolerated and 80% of the invasive breast cancer patients receiving this combination were disease-free at a 50 month follow-up [70]. Fabi et al. [71] also found that metastatic breast cancer patients pre-treated with anthracyclines and/or taxanes tolerated a combination treatment of capecitabine and celecoxib with little toxicity and a 47.5% clinical benefit rate, defined as CR plus stable disease of ≥6 months. Patients with tumor overexpression of COX-2 had a significantly longer time to progression and overall survival. Unfortunately, neither of these studies included an arm without celecoxib, so the authors could not conclude whether the inclusion of celecoxib in the chemotherapeutic regimen improved patient outcome. To our knowledge, only one study has been conducted of a celecoxib/chemotherapy combination that included an arm without celecoxib. This study assessed the benefit of epirubicin/cyclophosphamide followed by docetaxel with randomization to concurrent celecoxib (HER2− patients) or trastuzumab (HER2+ patients) in stage II–III patients. There was no significant difference in pCR between the HER2− patients that did (13%) and did not (11.5%) receive celecoxib, and the authors concluded that the addition of celecoxib to this drug regimen was unlikely to improve prognosis in this patient population [72].

As with the clinical trials of celecoxib/aromatase inhibitor combination treatments, there is no indication that the authors of these studies stratified their data by BMI category to analyze whether obese patients derived greater clinical benefit from the addition of celecoxib. However, Stephen Hursting’s laboratory has demonstrated that the tumor-promoting effects of diet-induced obesity were significantly reduced by omega 3 ethyl ester (Lovaza™, GlaxoSmithKline, UK) treatment in a xenograft model utilizing two mammary tumor cell lines derived from the MMTV-Wnt-1 transgenic mouse. Lovaza supplementation in the obese mice was also associated with lower mammary tumor COX-2 expression and PGE2 levels (personal communication). Given that the molecular profiles of the two cell lines used (one basal-like and one claudin-low) indicate that these tumors were estrogen-independent, these results suggest that the anti-tumor effects of Lovaza may be mediated by its suppression of COX-2 but not any subsequent reduction in aromatase expression. Consequently, we propose that obese breast cancer patients may benefit from the addition of treatments targeting the COX-2 pathway, regardless of their ERα status.

Conclusion

Obesity is known to be associated with a worse breast cancer prognosis as well as reduced response to aromatase inhibitors and chemotherapy. While the mechanism(s) mediating these effects are not completely understood, evidence from our laboratory and others suggests that increased COX-2 expression in tumor epithelial cells and local adipose-infiltrating macrophages could be playing an important role in the link between obesity and breast cancer progression. However, no clinical trial of COX-2 inhibitor treatment for breast cancer has specifically assessed its efficacy in obese patients. Additional research to examine the benefit of combining a COX-2 targeting drug with endocrine treatment and/or chemotherapy in this patient population is thus warranted.